Managing CAR-T Therapy: Side Effect Monitoring and Collaborative Patient Care
Panelists discuss how to monitor and manage adverse effects, particularly chimeric antigen receptor (CAR) T cell–specific reactions, in patients receiving this therapy and how to collaborate with the CAR T-cell therapy team during the treatment phase, emphasizing the most critical aspects of patient care at this stage.
Video content above is prompted by the following:
Dr Castaneda: Ask Jammie:
How do you monitor and manage adverse effects, particularly chimeric antigen receptor (CAR) T cell–specific reactions, in patients who receive this therapy?
Dr Castaneda: Ask Jammie:
How do you collaborate with the CAR T-cell therapy team during the treatment phase, and what aspects of patient care are most critical at this stage?
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
